Uremic Pruritus And Associated Dry Skin Pipeline Insight

"Uremic Pruritus and Associated Dry Skin Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Uremic Pruritus and Associated Dry Skin market. A detailed picture of the Uremic Pruritus and Associated Dry Skin pipeline landscape is provided, which includes the disease overview and Uremic Pruritus and Associated Dry Skin treatment guidelines. The assessment part of the report embraces in-depth Uremic Pruritus and Associated Dry Skin commercial assessment and clinical assessment of the Uremic Pruritus and Associated Dry Skin pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Uremic Pruritus and Associated Dry Skin collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Uremic Pruritus and Associated Dry Skin of Pipeline Development Activities

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Uremic Pruritus and Associated Dry Skin with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Uremic Pruritus and Associated Dry Skin treatment.
  • Uremic Pruritus and Associated Dry Skin key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Uremic Pruritus and Associated Dry Skin market.

 

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc. 

Uremic Pruritus and Associated Dry Skin Analytical Perspective by DelveInsight

In-depth Uremic Pruritus and Associated Dry Skin Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

 

Uremic Pruritus and Associated Dry Skin Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.

Scope of the Report

  • The Uremic Pruritus and Associated Dry Skin report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Uremic Pruritus and Associated Dry Skin across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Uremic Pruritus and Associated Dry Skin therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Uremic Pruritus and Associated Dry Skin research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Uremic Pruritus and Associated Dry Skin.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Uremic Pruritus and Associated Dry Skin.   
  • In the coming years, the Uremic Pruritus and Associated Dry Skin market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Uremic Pruritus and Associated Dry Skin R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Uremic Pruritus and Associated Dry Skin treatment market. Several potential therapies for Uremic Pruritus and Associated Dry Skin are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Uremic Pruritus and Associated Dry Skin market size in the coming years. 
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Uremic Pruritus and Associated Dry Skin) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions

  • What are the current options for Uremic Pruritus and Associated Dry Skin treatment?
  • How many companies are developing therapies for the treatment of Uremic Pruritus and Associated Dry Skin?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Uremic Pruritus and Associated Dry Skin?
  • How many Uremic Pruritus and Associated Dry Skin emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Uremic Pruritus and Associated Dry Skin?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Uremic Pruritus and Associated Dry Skin market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Uremic Pruritus and Associated Dry Skin? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Uremic Pruritus and Associated Dry Skin therapies?
  • What are the clinical studies going on for Uremic Pruritus and Associated Dry Skin and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Uremic Pruritus and Associated Dry Skin?
  • How many patents are granted and pending for the emerging therapies for the treatment of Uremic Pruritus and Associated Dry Skin?

1. Report Introduction

2. Uremic Pruritus and Associated Dry Skin

2.1. Overview

2.2. History

2.3. Uremic Pruritus and Associated Dry Skin Symptoms

2.4. Causes

2.5. Pathophysiology

2.6. Uremic Pruritus and Associated Dry Skin Diagnosis

2.6.1. Diagnostic Guidelines

3. Uremic Pruritus and Associated Dry Skin Current Treatment Patterns

3.1. Uremic Pruritus and Associated Dry Skin Treatment Guidelines

4. Uremic Pruritus and Associated Dry Skin - DelveInsight's Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Uremic Pruritus and Associated Dry Skin companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Uremic Pruritus and Associated Dry Skin Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Uremic Pruritus and Associated Dry Skin Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Uremic Pruritus and Associated Dry Skin Late Stage Products (Phase-III)

7. Uremic Pruritus and Associated Dry Skin Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Uremic Pruritus and Associated Dry Skin Discontinued Products

13. Uremic Pruritus and Associated Dry Skin Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report

14. Uremic Pruritus and Associated Dry Skin Key Companies

15. Uremic Pruritus and Associated Dry Skin Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Uremic Pruritus and Associated Dry Skin Unmet Needs

18. Uremic Pruritus and Associated Dry Skin Future Perspectives

19. Uremic Pruritus and Associated Dry Skin Analyst Review 

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

List of Table

Table 1: Uremic Pruritus and Associated Dry Skin Diagnostic Guidelines

Table 2: Uremic Pruritus and Associated Dry Skin Treatment Guidelines

Table 3: Assessment Summary

Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis

Table 5: Uremic Pruritus and Associated Dry Skin Acquisition Analysis

Table 6: Assessment by Phase of Development

Table 7: Assessment by Product Type (Mono / Combination)

Table 8: Assessment by Stage and Product Type

Table 9: Assessment by Route of Administration

Table 10: Assessment by Stage and Route of Administration

Table 11: Assessment by Molecule Type

Table 12: Assessment by Stage and Molecule Type

Table 13: Assessment by MOA

Table 14: Assessment by Stage and MOA

Table 15: Assessment by Target

Table 16: Assessment by Stage and Target

Table 17: Uremic Pruritus and Associated Dry Skin Late Stage Products (Phase-III)

Table 18: Uremic Pruritus and Associated Dry Skin mid Stage Products (Phase-II)

Table 19: Uremic Pruritus and Associated Dry Skin Early Stage Products (Phase-I)

Table 20: Pre-clinical and Discovery Stage Products

Table 21: Inactive Products

Table 22: Dormant Products

Table 23: Discontinued Products

List of Figures

Figure 1: Disease Overview

Figure 2: History

Figure 3: Symptoms

Figure 4: Causes

Figure 5: Pathophysiology

Figure 6: Diagnostic Guidelines

Figure 7: Treatment Guidelines

Figure 8: Uremic Pruritus and Associated Dry Skin companies collaborations, Licensing, Acquisition -Deal Value Trends

Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis

Figure 10: Uremic Pruritus and Associated Dry Skin Acquisition Analysis

Figure 11: Assessment by Phase of Development

Figure 12: Assessment by Product Type (Mono / Combination)

Figure 13: Assessment by Stage and Product Type

Figure 14: Assessment by Route of Administration

Figure 15: Assessment by Stage and Route of Administration

Figure 16: Assessment by Molecule Type

Figure 17: Assessment by Stage and Molecule Type

Figure 18: Assessment by MOA

Figure 19: Assessment by Stage and MOA

Figure 20: Late Stage Products (Phase-III)

Figure 21: Mid Stage Products (Phase-II)

Figure 22: Early Stage Products (Phase-I)

Figure 23: Pre-clinical and Discovery Stage Products

Figure 24: Inactive Products

Figure 25: Dormant Products

Figure 26: Discontinued Products

Figure 27: Unmet Needs

Forward to Friend

Need A Quote